Renal Autologous Cell Therapy (REACT)
Renal Autologous Cell Therapy (REACT) is a biological therapy with 8 clinical trials. Currently 1 active trials ongoing. Historical success rate of 80.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
3
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
66.7%
4 of 6 finished
33.3%
2 ended early
1
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
A Long-Term Follow-Up Study of Participants Exposed to REACT
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
A Study of Participants With Chronic Kidney Disease Previously Treated With REACT
Clinical Trials (8)
Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
A Long-Term Follow-Up Study of Participants Exposed to REACT
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
A Study of Participants With Chronic Kidney Disease Previously Treated With REACT
Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product
A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease
A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).
All 8 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 8